Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses
Elevated SARS-CoV-2 IgG4 levels following repeated COVID-19 mRNA boosters may impact blood and mucosal antibody functions against Omicron variants and sarbecoviruses.
Vaccination is vital to cardiovascular prevention, say heart specialists
The Society has published a Clinical Consensus Statement in the European Heart Journal highlighting the key role of vaccination in preventing cardiovascular events.
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection
Identifying host factors that mediate protection against newly-emergent viruses is needed for improved pandemic preparedness.
Global Respiratory Virus Activity by WHO
Global influenza and COVID-19 activity stayed low in late October 2025. COVID-19 was more common in northern regions, while influenza spread mainly in tropical areas.
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity.
News
Policy & Recommendations
Toward a Council Recommendation on the value of immunisation against respiratory infections
The Steering Group on the Prevention of Respiratory Infections launched a new manifesto at the #EURespiDay event held at the European Parliament in Brussels
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement
With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC
Mucosal COVID-19 vaccines in clinical development
Mucosal vaccines are designed to elicit both a strong systemic and mucosal immune response gaining importance as the next generation of vaccines
